Successful simultaneous targeting of IgE and IL-5 in a severe asthmatic patient selected for lung transplantation

Bergmann, Karl‐Christian; Oestmann, Jörg-Wilhelm; Bousquet, Jean; Zuberbier, Torsten

doi:10.1016/j.waojou.2022.100669

Cited by 1 publication

(2 citation statements)

References 15 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The simultaneous administration of omalizumab and an anti-IL5 biologic agent was the most commonly used combination in real-life studies for the treatment of severe, uncontrolled asthma. The main reasons reported by the authors of these studies for this strategy were an increase in blood eosinophil count, worsening of asthma symptoms, and OCS dependence on omalizumab therapy [23][24][25][26][28][29][30]. However, no data are provided in some studies regarding the reasons that led to starting a combination therapy instead of switching to anti-IL5 or how long it has been administered.…”

Section: Discussionmentioning

confidence: 99%

“…Bergmann et al [26] presented the case of a 53-year-old man with severe, uncontrolled allergic and eosinophilic asthma. The patient was already receiving maximal therapy with high doses of ICS and LABA, tiotropium, montelukast, and oral steroids, and was prescribed long-term oxygen therapy.…”

Section: Dual Biologic Therapy For Severe Asthma Insufficiently Contr...mentioning

confidence: 99%

See 1 more Smart Citation

Combination of Biological Therapy in Severe Asthma: Where We Are?

Carriera,

Fantò,

Martini

et al. 2023

JPM

View full text Add to dashboard Cite

Biological drugs have revolutionized the management of severe asthma. However, a variable number of patients remain uncontrolled or only partially controlled even after the appropriate administration of a biologic agent. The combination of two biologics may target different inflammatory pathways, and it has been used in patients suffering from uncontrolled severe asthma with evidence of both allergic and eosinophilic phenotypes or severe asthma and type2 comorbidities. Combination therapy has also been used to handle anti-IL4/13R induced hypereosinophilia. There is insufficient data on combining biologics for the treatment of severe uncontrolled asthma and type 2 comorbidities, also because of the high cost, and currently no guideline recommends dual biologic therapy. A systematic search was performed using the Medline and Scopus databases. Published data on concurrent administration of two biological drugs in severe, uncontrolled asthma patients has been reported in 28 real-world studies and 1 clinical trial. Data extraction was followed by a descriptive and narrative synthesis of the findings. Future studies should be conducted to further assess the safety, efficacy, and cost-effectiveness of this therapeutic strategy.

show abstract